Equity
Share-Based Payment - Unrecognized Cost of Nonvested Awards
Moderna Share-Based Payment - Unrecognized Cost of Nonvested Awards increased by 27.0% to $978.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 11.1%, from $1.10B to $978.00M. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryEfficiency
SignalLower is better
VolatilityModerate
First reportedQ1 2019
Last reportedQ1 2026May 1, 2026
How to read this metric
An increase suggests higher future non-cash compensation expenses, which may impact future operating margins.
Detailed definition
This represents the total compensation expense for stock-based awards that has been granted but not yet recognized in th...
Peer comparison
Common in large-cap companies that utilize equity-based compensation to align employee and shareholder interests.
Metric ID:
share_based_payment_unrecognized_costHistorical Data
15 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $336.00M | $348.00M | $538.00M | $575.00M | $529.00M | $789.00M | $743.00M | $701.00M | $1.20B | $1.00B | $875.00M | $1.10B | $908.00M | $770.00M | $978.00M |
| QoQ Change | — | +3.6% | +54.6% | +6.9% | -8.0% | +49.1% | -5.8% | -5.7% | +71.2% | -16.7% | -12.5% | +25.7% | -17.5% | -15.2% | +27.0% |
| YoY Change | — | — | — | +71.1% | +52.0% | +46.7% | +29.2% | +32.5% | +52.1% | +34.6% | +24.8% | -8.3% | -9.2% | -12.0% | -11.1% |
Range$336.00M – $1.20B
CAGR+35.7%
Avg YoY Growth+25.2%
Median YoY Growth+30.9%
Share-Based Payment - Unrecognized Cost of Nonvested Awards at Other Companies
Frequently Asked Questions
- What is Moderna's share-based payment - unrecognized cost of nonvested awards?
- Moderna (MRNA) reported share-based payment - unrecognized cost of nonvested awards of $978.00M in Q1 2026.
- How has Moderna's share-based payment - unrecognized cost of nonvested awards changed year-over-year?
- Moderna's share-based payment - unrecognized cost of nonvested awards decreased by 11.1% year-over-year, from $1.10B to $978.00M.
- What does share-based payment - unrecognized cost of nonvested awards mean?
- The amount of future compensation expense for stock awards that have been granted but not yet earned by employees.